Source-grounded facts extracted from NANOVIRICIDES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
NANOVIRICIDES, INC. entered into Placement Agency Agreement with D. Boral Capital LLC (the "Placement Agent") (effective 2026-05-15).
“the Company entered into a Placement Agency Agreement with D. Boral Capital LLC (the "Placement Agent"), dated May 15, 2026, pursuant to which the Placement Agent acted as the exclusive placement agent for the Company in connection with the Offering (the "Placement Agency Agreement")”
NANOVIRICIDES, INC. entered into Securities Purchase Agreement with a certain purchaser (the "Investor") valued at approximately $2.0 million (effective 2026-05-15).
“On May 15, 2026, NanoViricides, Inc. (the "Company") and a certain purchaser (the "Investor") entered into a securities purchase agreement (the "Securities Purchase Agreement")”
NANOVIRICIDES, INC. issued Series A Common Stock Purchase Warrants to purchase up to 3,571,429 shares of Common Stock and Series B Common Stock Purchase Warrants to purchase up to 3,571,4 of warrant to a certain institutional investor.
“The information contained above in Item 1.01 relating to the issuance of the Common Warrants and the shares of Common Stock issuable thereunder is hereby incorporated by reference into this Item 3.02.”
NANOVIRICIDES, INC. entered into Sales Agreement with EF Hutton LLC (effective 2024-04-05).
“On April 5, 2024, a new Sales Agreement (the “Sales Agreement”) was executed to name EF Hutton LLC as the sole sales agent (the “Agent”) and to remove B. Riley Securities, Inc. as a Sales Agent.”
NANOVIRICIDES, INC. amended a license with TheraCour Pharma, Inc. (effective 2024-02-12).
“nto a License Agreement (the “License Agreement”) with TheraCour Pharma, Inc. (“TheraCour”) for an exclusive, worldwide license to the Company for further development with respect to TheraCour’s research and development of services with respect”
NANOVIRICIDES, INC. entered into Line of Credit Agreement with Dr. Anil R. Diwan valued at $2,000,000 (effective 2023-11-13).
“on November 13, 2023, the Company and the Company’s President and CEO, Dr. Anil R. Diwan, entered into a Line of Credit Agreement whereby Dr. Diwan agreed to provide a standby Line of Credit to the Company in the maximum amount of $2,000,000.”
NANOVIRICIDES, INC. amended Extension Agreement with Dr. Anil R. Diwan valued at $2,000,000 (effective 2024-02-12).
“On February 12, 2024, the Company, pursuant to Article 2.5 of the Company’s Line of Credit Agreement with Dr. Anil R. Diwan, signed an Extension Agreement which extended the maturity date of the Company’s Line of Credit from December 31, 2024 to December 31, 2025.”
NANOVIRICIDES, INC. amended Amendment with TheraCour Pharma, Inc. (effective 2024-02-13).
“Amendment to Coronavirus License Agreement As previously disclosed, on September 9, 2021, NanoViricides, Inc. (the “Company”) entered”
NANOVIRICIDES, INC. entered into License Agreement with TheraCour Pharma, Inc. (effective 2021-09-09).
“NanoViricides, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with TheraCour Pharma, Inc. (“TheraCour”) for an exclusive, worldwide license to the Company for further development with respect to TheraCour’s research and development of services with respect to treatments for coronavirus derived human infections.”
NANOVIRICIDES, INC. shareholders approved Ratification of the appointment of EisnerAmper, LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024 at the 2024-01-13 meeting.
“Proposal 4 – To ratify the appointment of EisnerAmper, LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024: Votes For Votes Against Votes Abstained 9,165,259 152,847 125,594”
NANOVIRICIDES, INC. shareholders approved Approval of an award of 10,204 Series A Preferred Shares to Anil Diwan in connection with the extension of his employment as the Company’s President at the 2024-01-13 meeting.
“Proposal 3 – Approval of Convertible Preferred Stock Grant to Anil Diwan: Votes For Votes Against Votes Abstained Broker Non-Votes 5,508,046 844,079 34,609 3,056,966”
NANOVIRICIDES, INC. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2024-01-13 meeting.
“Proposal 2 – Advisory Vote on Compensation of Named Executive Officers: Votes For Votes Against Votes Abstained Broker Non-Votes 5,572,378 788,423 25,933 3,056,966”
NANOVIRICIDES, INC. shareholders approved Re-election of Anil Diwan as a Class I Director for a two-year term expiring at the 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier resignation or removal at the 2024-01-13 meeting.
“Proposal 1 – Election of Director - Re-Election of Anil Diwan as a Class I Director: Votes For Votes Against Votes Abstained Broker Non-Votes 5,590,467 308,092 488,175 3,056,966”
NANOVIRICIDES, INC. incurred convertible notes of $1,500,000 with TheraCour Pharma, Inc. at twelve percent (12%) per annum maturing January 19, 2025.
“by TheraCour within 3 months from Regulatory Approval. Upon achieving this milestone, the Registrant was obligated to pay TheraCour a cash milestone payment in the amount of $1,500,000. In lieu of this cash payment, TheraCour agreed to accept a Convertible Promissory Note in the principal amount of $1,500,000 effective July 19, 2023 (the “Note”). The”
NANOVIRICIDES, INC. entered into Deferred Expense Exchange Agreement with TheraCour Pharma, Inc. valued at $1,500,000 Convertible Promissory Note; interest rate 12% per annum; due 2025-01-19 (effective 2023-07-19).
“On August 29, 2023, NanoViricides, Inc. (the “Registrant”) entered into a Deferred Expense Exchange Agreement (the “Agreement”) with TheraCour Pharma, Inc., a Connecticut corporation (“TheraCour”) effective as of July 19, 2023.”
NANOVIRICIDES, INC. entered into License Agreement with Karveer Meditech Private Limited (effective 2023-03-27).
“On March 27, 2023, NanoViricides, Inc. (the “Company”) entered into a License Agreement (the “Agreement”) with Karveer Meditech Private Limited (“Karveer”)”
NANOVIRICIDES, INC. shareholders approved The Redomicile of the Company as a Delaware Corporation at the 2023-02-07 meeting.
“Proposal 1 – The Redomicile of the Company as a Delaware Corporation: Votes For Votes Against/Withheld 8,115,210 942,379”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.